Detailed results from the Phase III OASIS-4 study have found that Bayer’s elinzanetant showed a statistically significant ...

Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent ...

US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved a new Opdivo (nivolumab) ...

The Alliance for Clinical Trials in Oncology has announced results from ATOMIC, a Phase III trial evaluating standard ...

US biotech Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a strategic in-licensing agreement with China’s ...

US pharma major Bristol Myers Squibb (NYSE: BMY) has entered into an agreement for the global co-development and ...

With ASCO 2025 drawing towards a close in Chicago, Amsterdam-based biotech Avidicure is entering the spotlight with its first ...

Netherlands-based biotech VectorY Therapeutics, which is developing treatments for neurodegenerative diseases, today ...

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...

AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its ...

Arcus Biosciences (NYSE: RCUS) is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early ...

A clinical-stage biotech company developing oral therapies for movement disorders, with an initial focus on dystonia.